|
|||||
|
|
Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of Alzheimer type |
|
| Authors: | I. Bergman G. Brane C. G. Gottfries K. -G. Jostell I. Karlsson L. Svennerholm |
| Affiliation: | 1. Clinical Research Department, Astra L?kemedel AB, S-15185, S?dert?lje, Sweden 2. Department of Psychiatry and Neurochemistry, University of G?teborg, St. J?rgen's Hospital, Hisings Backa, S-42203, Sweden 3. Research and Development Laboratories, Astra L?kemedel AB, S-15185, S?dert?lje, Sweden |
| Abstract: | Alaproclate, a specific inhibitor of neuronal serotonin re-uptake, was given to 12 patients with dementia of Alzheimer type. The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated. Plasma protein binding for alaproclate was 82 +/- 1%. Two weeks of repeated administration produced plasma concentrations of alaproclate similar to those predicted from a single dose. The pharmacological effect of the drug was demonstrated by an inhibition of serotonin uptake in the patients' platelets and a reduction of the serotonin concentration in blood. Global rating of clinical efficacy showed a positive effect of alaproclate in five of the patients, mainly regarding emotional functions. |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |